423 related articles for article (PubMed ID: 28554189)
1. Structure of the human multidrug transporter ABCG2.
Taylor NMI; Manolaridis I; Jackson SM; Kowal J; Stahlberg H; Locher KP
Nature; 2017 Jun; 546(7659):504-509. PubMed ID: 28554189
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2.
Jackson SM; Manolaridis I; Kowal J; Zechner M; Taylor NMI; Bause M; Bauer S; Bartholomaeus R; Bernhardt G; Koenig B; Buschauer A; Stahlberg H; Altmann KH; Locher KP
Nat Struct Mol Biol; 2018 Apr; 25(4):333-340. PubMed ID: 29610494
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states.
Manolaridis I; Jackson SM; Taylor NMI; Kowal J; Stahlberg H; Locher KP
Nature; 2018 Nov; 563(7731):426-430. PubMed ID: 30405239
[TBL] [Abstract][Full Text] [Related]
4. Structure of the Human Cholesterol Transporter ABCG1.
Skarda L; Kowal J; Locher KP
J Mol Biol; 2021 Oct; 433(21):167218. PubMed ID: 34461069
[TBL] [Abstract][Full Text] [Related]
5. Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter.
László L; Sarkadi B; Hegedűs T
PLoS One; 2016; 11(10):e0164426. PubMed ID: 27741279
[TBL] [Abstract][Full Text] [Related]
6. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
Ozvegy-Laczka C; Várady G; Köblös G; Ujhelly O; Cervenak J; Schuetz JD; Sorrentino BP; Koomen GJ; Váradi A; Német K; Sarkadi B
J Biol Chem; 2005 Feb; 280(6):4219-27. PubMed ID: 15557326
[TBL] [Abstract][Full Text] [Related]
7. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers.
Bhatia A; Schäfer HJ; Hrycyna CA
Biochemistry; 2005 Aug; 44(32):10893-904. PubMed ID: 16086592
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation.
Rosenberg MF; Bikadi Z; Hazai E; Starborg T; Kelley L; Chayen NE; Ford RC; Mao Q
Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1725-35. PubMed ID: 26249353
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2.
Kowal J; Ni D; Jackson SM; Manolaridis I; Stahlberg H; Locher KP
J Mol Biol; 2021 Jun; 433(13):166980. PubMed ID: 33838147
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the central tyrosines of putative cholesterol recognition amino acid consensus (CRAC) sequences modify folding, activity, and sterol-sensing of the human ABCG2 multidrug transporter.
Gál Z; Hegedüs C; Szakács G; Váradi A; Sarkadi B; Özvegy-Laczka C
Biochim Biophys Acta; 2015 Feb; 1848(2):477-87. PubMed ID: 25445676
[TBL] [Abstract][Full Text] [Related]
11. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.
Telbisz Á; Özvegy-Laczka C; Hegedűs T; Váradi A; Sarkadi B
Biochem J; 2013 Mar; 450(2):387-95. PubMed ID: 23205634
[TBL] [Abstract][Full Text] [Related]
12. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Anreddy N; Patel A; Zhang YK; Wang YJ; Shukla S; Kathawala RJ; Kumar P; Gupta P; Ambudkar SV; Wurpel JN; Chen ZS; Guo H
Oncotarget; 2015 Nov; 6(36):39276-91. PubMed ID: 26515463
[TBL] [Abstract][Full Text] [Related]
13. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.
Telbisz A; Müller M; Ozvegy-Laczka C; Homolya L; Szente L; Váradi A; Sarkadi B
Biochim Biophys Acta; 2007 Nov; 1768(11):2698-713. PubMed ID: 17662239
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
15. Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.
Ozvegy-Laczka C; Laczkó R; Hegedus C; Litman T; Várady G; Goda K; Hegedus T; Dokholyan NV; Sorrentino BP; Váradi A; Sarkadi B
J Biol Chem; 2008 Sep; 283(38):26059-70. PubMed ID: 18644784
[TBL] [Abstract][Full Text] [Related]
16. Cryo-EM structure of human ABCB8 transporter in nucleotide binding state.
Li S; Ren Y; Lu X; Shen Y; Yang X
Biochem Biophys Res Commun; 2021 Jun; 557():187-191. PubMed ID: 33872987
[TBL] [Abstract][Full Text] [Related]
17. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
Li YF; Polgar O; Okada M; Esser L; Bates SE; Xia D
J Mol Graph Model; 2007 Mar; 25(6):837-51. PubMed ID: 17027309
[TBL] [Abstract][Full Text] [Related]
18. Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1.
Alam A; Küng R; Kowal J; McLeod RA; Tremp N; Broude EV; Roninson IB; Stahlberg H; Locher KP
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E1973-E1982. PubMed ID: 29440498
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis of the Allosteric Inhibition of Human ABCG2 by Nanobodies.
Irobalieva RN; Manolaridis I; Jackson SM; Ni D; Pardon E; Stahlberg H; Steyaert J; Locher KP
J Mol Biol; 2023 Oct; 435(19):168234. PubMed ID: 37597690
[TBL] [Abstract][Full Text] [Related]
20. The transport pathway in the ABCG2 protein and its regulation revealed by molecular dynamics simulations.
Nagy T; Tóth Á; Telbisz Á; Sarkadi B; Tordai H; Tordai A; Hegedűs T
Cell Mol Life Sci; 2021 Mar; 78(5):2329-2339. PubMed ID: 32979053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
